DelveInsight’s, “Celiac Disease Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Celiac Disease pipeline landscape. It covers the Celiac Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Celiac Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Celiac Disease Pipeline Report

• DelveInsight’s Celiac Disease pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Celiac Disease treatment.
• The leading companies working in the Celiac Disease Market include 9 Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.
• Promising Celiac Disease Pipeline Therapies in the various stages of development include TIMP-GLIA, Larazotide Acetate, TPM502, Latiglutenase, DONQ52, TAK-062, and others.
• April 2023: Millennium Pharmaceuticals Inc. announced a study of phase 1 clinical trials for PvP001 100 mg. The study is in 4 parts. At the start of each part of the study, the study doctor will check to determine who can take part at the first study visit. Different groups of participants will be in different parts of the study.
• September 2023: Takeda announced a study of phase 2 clinical trials for TAK-062. The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

 

Request a sample and discover the recent advances in Celiac Disease Treatment Drugs @ Celiac Disease Pipeline Report

 

In the Celiac Disease pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Celiac Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Celiac Disease Overview

Celiac disease is a serious autoimmune disease that occurs in genetically predisposed people where the ingestion of gluten leads to damage in the small intestine. It is estimated to affect 1 in 100 people worldwide. Two and one-half million Americans are undiagnosed and are at risk for long-term health complications. Celiac disease is hereditary, meaning that it runs in families.

 

Find out more about Celiac Disease Therapeutics Assessment @ Celiac Disease Preclinical and Discovery Stage Products

 

Celiac Disease Emerging Drugs Profile

• Larazotide – 9 Meters Biopharma
• CNP- 101: Cour Pharmaceutical
• Latiglutenase: Immunogenics
• Ordesekimab – Amgen
• CALY 002: Calypso Biotech
• BNZ-2: Bioniz

 

Celiac Disease Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the Celiac Disease therapies. The Celiac Disease companies which have their Celiac Disease drug candidates in the most advanced stage, i.e. phase III include, 9 Meters Biopharma.

 

Learn more about the emerging Celiac Disease Pipeline Therapies @ Celiac Disease Clinical Trials Assessment

 

Scope of the Celiac Disease Pipeline Report

• Coverage- Global
• Celiac Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Celiac Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Celiac Disease Companies- Metres Biopharma, Amgen, Allero Therapeutics, Takeda, Calypso Biotech, Anokion, Zedira GmbH, Millennium Pharmaceuticals, ImmunogenX, GlaxoSmithKline, ImmusanT, ActoBio Therapeutics, Amyra biotech, and others.
• Celiac Disease Pipeline Therapies- TIMP-GLIA, Larazotide Acetate, TPM502, Latiglutenase, DONQ52, TAK-062, and others.

 

Dive deep into rich insights for new drugs for Celiac Disease Treatment, Visit @ Celiac Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Celiac Disease: Overview
4. Celiac Disease Pipeline Therapeutics
5. Celiac Disease Therapeutic Assessment
6. Celiac Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Larazotide – 9 Meters Biopharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Ordesekinab: Amgen
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Caly002: Calypso Biotech
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. BNZ-2: Bioniz
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Celiac Disease Key Companies
21. Celiac Disease Key Products
22. Celiac Disease- Unmet Needs
23. Celiac Disease Market Drivers and Barriers
24. Celiac Disease Future Perspectives and Conclusion
25. Celiac Disease Analyst Views
26. Celiac Disease Companies
27. Appendix

 

For further information on the Celiac Disease Pipeline therapeutics, reach out to Celiac Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking